Lunaphore Technologies SA, a Lausanne, Switzerland-based life-sciences company developing innovative next-generation equipment for cancer research and tissue diagnostics, held the first closing of its Series C funding, amounting to CHF23M.
The round was led by the Japanese strategic investor PHC Holdings Corporation (hereafter, PHCHD), a global healthcare company that owns Epredia, a provider of comprehensive solutions for precision cancer diagnostics, with participation from Redalpine Venture Partners, OCCIDENT and Alpana Ventures. James Post, President of Epredia, a PHC Group portfolio company, joined Lunaphore’s Board of Directors as part of the transaction.
The company intends to use the funds for market and product expansion. This includes a US market entry, the ramp up of activities in Europe and the development of next generation of instruments.
Led by Ata Tuna Ciftlik, CEO, Lunaphore Technologies develops next generation tissue autostainers. The technology, based on microfluidics is called FFeX (Fast Fluidic Exchange), aims to perform assays much faster than standard techniques and has demonstrated good results in tests with cancer patient samples. Epredia was created in June 2019 following the acquisition of Thermo Fisher Scientific’s Anatomical Pathology business by PHC Holdings Corporation.